Today: 10 April 2026
Subscribe
Browse Category

NYSE:JNJ 23 January 2026 - 4 February 2026

Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson shares rose about 1% Tuesday to $233.10 after RBC Capital Markets raised its price target, citing ongoing talc litigation risk. The company highlighted new real-world data showing ERLEADA cut death risk by 51% in certain prostate cancer patients. Investors await management’s next comments at the TD Cowen conference on March 3.
4 February 2026
··
Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson shares closed Friday nearly flat at $227.25 after EU advisers backed expanded use of its prostate cancer drug Akeega. The Committee for Medicinal Products for Human Use recommended approval for patients with BRCA1/2 mutations. The final decision rests with the European Commission. Traders are watching Monday’s open and upcoming U.S. economic data.
1 February 2026
···
Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs

Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs

Johnson & Johnson shares slipped 0.1% to $227.43 by midday Thursday after peaking near record highs, following a Morgan Stanley upgrade and a price target hike to $262. The FDA approved a new Darzalex Faspro combination for multiple myeloma on Jan. 27. CEO Joaquin Duato’s spouse sold 100,000 shares last week, SEC filings show. J&J forecasts 2026 sales up to $100.5 billion and EPS up to $11.63.
29 January 2026
··
Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen

Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen

Johnson & Johnson shares rose 1.5% to $227.72 Wednesday after Morgan Stanley upgraded the stock and raised its price target to $262. The FDA approved expanded use of J&J’s Darzalex Faspro for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. A regulatory filing showed CEO Joaquin Duato’s spouse sold about $22 million in shares.
29 January 2026
··
Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Johnson & Johnson shares rose 1.2% to $227.06 after the FDA approved Darzalex Faspro for use with the VRd regimen in newly diagnosed multiple myeloma patients ineligible for stem cell transplant. The approval is based on the CEPHEUS trial, which showed improved outcomes. The move comes as Medicare named 15 drugs for future price negotiations, pressuring the sector.
28 January 2026
··
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson shares rose 1.3% Tuesday after the FDA approved a Darzalex Faspro combination for newly diagnosed multiple myeloma patients ineligible for stem-cell transplants. The S&P 500 closed at a record high, while healthcare stocks broadly fell after a Medicare payment proposal. The U.S. also named 15 drugs for future Medicare price negotiations, increasing pressure on big pharma.
28 January 2026
···
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
Johnson & Johnson stock is nudging higher — here’s what traders are watching this week

Johnson & Johnson stock is nudging higher — here’s what traders are watching this week

Johnson & Johnson shares rose 0.4% to $221.01 Monday as investors awaited the Federal Reserve’s Jan. 28 decision and major tech earnings. The company projected 2026 adjusted earnings per share of $11.43–$11.63 and sales up to $101 billion. A court-appointed special master recommended allowing expert testimony that J&J’s talc caused ovarian cancer, raising the risk of federal trials. J&J denies the allegations.
26 January 2026
·
Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

The Health Care Select Sector SPDR Fund (XLV) fell 0.5% to $157.48 Friday, with Eli Lilly down 2.1%. Johnson & Johnson and UnitedHealth posted small gains. Traders are watching obesity-drug demand and a crowded earnings calendar next week. The FDA linked ByHeart’s recalled infant formula to a multi-state botulism outbreak.
25 January 2026
·····
Johnson & Johnson stock ends higher; what to watch for JNJ price after Fed week and talc risk

Johnson & Johnson stock ends higher; what to watch for JNJ price after Fed week and talc risk

Johnson & Johnson shares rose 0.76% to $220.14 at Friday’s close, outpacing other major pharma stocks. The company reaffirmed its 2026 sales and profit targets after posting Q4 sales of $24.6 billion and adjusted EPS of $2.46. Legal risks remain as a special master recommended expert testimony in federal talc lawsuits. Investors await the Federal Reserve’s rate decision on Wednesday.
25 January 2026
··
Johnson & Johnson stock price ends week near $220 as Wall Street hikes targets — what to watch next

Johnson & Johnson stock price ends week near $220 as Wall Street hikes targets — what to watch next

Johnson & Johnson shares closed Friday up 0.8% at $220.14 after TD Cowen and Citi raised price targets to $250, citing strong 2026 guidance. Q4 2025 sales reached $24.6 billion with adjusted EPS at $2.46. A court special master recommended allowing expert testimony in federal talc lawsuits. The company declared a $1.30 quarterly dividend, payable March 10.
24 January 2026
·
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.
23 January 2026
·····
1 2 3 4 … 8

Stock Market Today

  • U.S. Stocks Rally as Middle East Ceasefire Talks Boost Market Sentiment
    April 9, 2026, 7:38 PM EDT. U.S. stocks continued a strong run with the S&P 500 and Nasdaq extending their winning streaks to seven sessions, buoyed by optimism around ceasefire talks in the Middle East. The Philadelphia Semiconductor Index hit a record high, supported by gains from Amazon, Intel, Nike, and Brown-Forman. Oil prices rose modestly, settling near $98 a barrel amid tight supply concerns and restrictions on the Strait of Hormuz, a key oil shipping route. Bitcoin broke above $72,000, reflecting broader risk appetite. Market attention remains fixed on whether the ceasefire and direct Israel-Lebanon negotiations can be sustained, with U.S. Treasury yields largely unchanged. Analysts caution the S&P 500's 6,800 level is pivotal, noting sentiment balances positive headlines with skepticism. The memory sector's rally continues, and options data signals key technical support levels for market stability.

Latest article

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

9 April 2026
Meta Platforms signed a new $21 billion deal with CoreWeave for AI cloud computing capacity through 2032, according to a securities filing. CoreWeave shares rose 3.4% in after-hours trading. The agreement adds to a $14.2 billion commitment disclosed last September. CoreWeave also launched $3 billion in convertible notes and upsized a senior-notes deal to $1.75 billion.
Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

9 April 2026
Tesla is developing a lower-cost compact SUV, with initial production planned for Shanghai, Reuters reported Thursday. The company built 408,386 vehicles and delivered 358,023 in the first quarter, leaving its widest gap in at least four years. Reuters said the new SUV likely will not reach production this year. Tesla did not respond to questions about the project.
NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

9 April 2026
NIO opened pre-orders for its ES9 flagship SUV Thursday, pricing it at 528,000 yuan with battery or 420,000 yuan under its Battery-as-a-Service plan. March deliveries rose 136% year-on-year, but NIO’s U.S. shares fell 4.9% after the announcement. The ES9 enters a shrinking premium SUV market in China, competing with Li Auto and Aito. CEO William Li warned chip shortages could add up to 10,000 yuan per vehicle.
Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

9 April 2026
Plug Power shares rose 2.5% to $2.715 Thursday after the company reaffirmed its target of positive EBITDAS by end-2026 and projected up to $200 million in savings from Project Quantum Leap. The update followed a major electrolyzer project win in Quebec and investor meetings in Toronto and Montreal. Plug reported 2025 revenue of $710 million and a fourth-quarter gross profit of $5.5 million.
Go toTop